Ozagrel HCl (78712-43-3) is a potent and selective inhibitor of thromboxane (TXA2) synthetase (IC50 = 4 nM).1?Does not inhibit prostacyclin (PGI2) synthase, cyclooxygenase or PGE2?isomerase (IC50 > 1 mM).1?Inhibits platelet aggregation2?in vitro?and arachidonate-induced arterial contraction?in vivo. Ozagrel HCl protects against arachidonate-induced sudden death in the rabbit3, and alleviates liver injury induced by acetaminophen overdose in mice4.
Ozagrel Hydrochloride is a selective thromboxane A2 synthase inhibitor, which alleviates liver injury induced by acetaminophen overdose in mice.
Antithrombotic;Thromboxane synthase inhibitor
ChEBI: Ozagrel hydrochloride is an organic molecular entity.
1) Hiraku?et al. (1986),?Pharmacological studies on the TXA2?synthetase inhibitor (E)-3-[p-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid (OKY-046); Jpn. J. Pharmacol.,?41?393
2) Naito?et al. (1983), Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets; Eur. J. Pharmacol.,?91?41
3) Edmonds and Leffer (1984),?Protective actions of a new thromboxane synthetase inhibitor in arachidonate induced sudden death; Life Sci.,?35?1763
4) Tomishima?et al. (2013),?Ozagrel hydrochloride, a selective thromboxane A2?synthase inhibitor, alleviates liver injury induced by acetaminophen overdose in mice; BMC Gastroenterol.,?30?13
